AU2010303628B2 - A method for diagnosing primary biliary cirrhosis (PBC) using novel autoantigens - Google Patents

A method for diagnosing primary biliary cirrhosis (PBC) using novel autoantigens Download PDF

Info

Publication number
AU2010303628B2
AU2010303628B2 AU2010303628A AU2010303628A AU2010303628B2 AU 2010303628 B2 AU2010303628 B2 AU 2010303628B2 AU 2010303628 A AU2010303628 A AU 2010303628A AU 2010303628 A AU2010303628 A AU 2010303628A AU 2010303628 B2 AU2010303628 B2 AU 2010303628B2
Authority
AU
Australia
Prior art keywords
pbc
elisa
assay
autoantigen
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010303628A
Other languages
English (en)
Other versions
AU2010303628A1 (en
Inventor
Donald B. Bloch
Mark J. Lim
Heather P. Ostendorff
Kenneth J. Rothschild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Ambergen Inc
Original Assignee
General Hospital Corp
Ambergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43857083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010303628(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Ambergen Inc filed Critical General Hospital Corp
Publication of AU2010303628A1 publication Critical patent/AU2010303628A1/en
Application granted granted Critical
Publication of AU2010303628B2 publication Critical patent/AU2010303628B2/en
Priority to AU2015238816A priority Critical patent/AU2015238816B2/en
Assigned to MASSACHUSETTS GENERAL HOSPITAL, AMBERGEN, INC. reassignment MASSACHUSETTS GENERAL HOSPITAL Request to Amend Deed and Register Assignors: AMBERGEN, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2010303628A 2009-10-05 2010-10-05 A method for diagnosing primary biliary cirrhosis (PBC) using novel autoantigens Active AU2010303628B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015238816A AU2015238816B2 (en) 2009-10-05 2015-10-07 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24876809P 2009-10-05 2009-10-05
US61/248,768 2009-10-05
PCT/US2010/051475 WO2011044125A1 (en) 2009-10-05 2010-10-05 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015238816A Division AU2015238816B2 (en) 2009-10-05 2015-10-07 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens

Publications (2)

Publication Number Publication Date
AU2010303628A1 AU2010303628A1 (en) 2012-04-12
AU2010303628B2 true AU2010303628B2 (en) 2015-07-09

Family

ID=43857083

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2010303628A Active AU2010303628B2 (en) 2009-10-05 2010-10-05 A method for diagnosing primary biliary cirrhosis (PBC) using novel autoantigens
AU2015238816A Active AU2015238816B2 (en) 2009-10-05 2015-10-07 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2015238816A Active AU2015238816B2 (en) 2009-10-05 2015-10-07 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens

Country Status (7)

Country Link
US (4) US8852956B2 (enExample)
EP (2) EP2486407B1 (enExample)
JP (2) JP5710623B2 (enExample)
AU (2) AU2010303628B2 (enExample)
CA (2) CA2776688C (enExample)
ES (2) ES2566762T3 (enExample)
WO (1) WO2011044125A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2486407B1 (en) * 2009-10-05 2016-02-10 Ambergen Inc. A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens
CN102627695B (zh) * 2012-03-23 2014-10-22 中国医学科学院北京协和医院 原发性胆汁性肝硬化特异性自身抗原及其应用
CN104292322A (zh) * 2012-03-23 2015-01-21 中国医学科学院北京协和医院 原发性胆汁性肝硬化特异性自身抗原及其应用
CN104292323B (zh) * 2012-03-23 2017-04-05 中国医学科学院北京协和医院 原发性胆汁性肝硬化特异性自身抗原及其应用
WO2020190700A1 (en) * 2019-03-15 2020-09-24 Chan Zuckerberg Biohub, Inc. Autoantibodies as biomarker of paraneoplastic encephalitis associated with testicular cancer
AU2022206267B2 (en) * 2021-01-08 2025-11-20 Inova Diagnostics, Inc. Compositions and methods for diagnosing primary biliary cirrhosis
CN113009148A (zh) * 2021-02-10 2021-06-22 中国医学科学院北京协和医院 用于诊断抗sp100抗体阳性与阴性pbc患者的糖链标志物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
CA1341231C (en) * 1986-12-16 2001-05-15 Ross Leon Coppel Primary biliary cirrhosis autoantigen
JPH03291568A (ja) * 1990-04-09 1991-12-20 Igaku Seibutsugaku Kenkyusho:Kk 抗ミトコンドリアｍ↓２抗体の検出用試薬及び測定法
JP3472048B2 (ja) * 1995-10-09 2003-12-02 鐘淵化学工業株式会社 自己免疫疾患の診断薬
CA2256684A1 (en) * 1996-06-24 1997-12-31 Patrick Leung Recombinant fusion protein comprising pdc-e2, bcoadc-e2, and ogdc-e2 and uses thereof
JPH1138008A (ja) * 1997-07-16 1999-02-12 Sumitomo Electric Ind Ltd 自己抗体の検出方法および検出試薬
WO2002008383A2 (en) * 2000-07-24 2002-01-31 The General Hospital Corporation Sp110, a polypeptide component of the nuclear body
AU2002254431A1 (en) * 2001-03-27 2002-10-08 M. Eric Gershwin Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
WO2005072748A1 (en) * 2004-01-21 2005-08-11 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
JP2006071409A (ja) * 2004-09-01 2006-03-16 Kansai Tlo Kk シェーグレン症候群診断キット
WO2007043103A1 (ja) * 2005-09-30 2007-04-19 Kansai Technology Licensing Organization Co., Ltd. シェーグレン症候群診断法及び診断キット
JP2007245505A (ja) 2006-03-15 2007-09-27 Fujifilm Corp 平版印刷版原版、平版印刷版およびその作製方法
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
JP5471724B2 (ja) 2009-09-30 2014-04-16 大日本印刷株式会社 化粧シート
EP2486407B1 (en) * 2009-10-05 2016-02-10 Ambergen Inc. A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens
JP2012206482A (ja) 2011-03-30 2012-10-25 Daikyonishikawa Corp 樹脂成形品の組付け構造

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SELMI, C. et al. Clinical Reviews in Allergy and Immunology, 2005, Vol.28, p.73-81. *

Also Published As

Publication number Publication date
WO2011044125A8 (en) 2012-09-13
US20240159749A1 (en) 2024-05-16
AU2010303628A1 (en) 2012-04-12
EP2486407A1 (en) 2012-08-15
CA2965189A1 (en) 2011-04-14
JP5710623B2 (ja) 2015-04-30
EP3012631B1 (en) 2018-05-23
AU2015238816B2 (en) 2017-10-05
US20120244562A1 (en) 2012-09-27
US11885802B2 (en) 2024-01-30
US20150057170A1 (en) 2015-02-26
US20170307607A1 (en) 2017-10-26
ES2681839T3 (es) 2018-09-17
JP6012794B2 (ja) 2016-10-25
AU2015238816A1 (en) 2015-10-29
US8852956B2 (en) 2014-10-07
JP2013506837A (ja) 2013-02-28
CA2776688C (en) 2017-06-20
CA2965189C (en) 2020-06-30
WO2011044125A1 (en) 2011-04-14
EP2486407B1 (en) 2016-02-10
EP2486407A4 (en) 2013-04-10
JP2015143695A (ja) 2015-08-06
ES2566762T3 (es) 2016-04-15
CA2776688A1 (en) 2011-04-14
EP3012631A1 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
US20240159749A1 (en) Method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens
Amlani et al. Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis
US11199549B2 (en) MEl'hods and means for diagnosing spondylarthritis using autoantibody markers
Pividori et al. Electrochemical immunosensor for the diagnosis of celiac disease
US20130171659A1 (en) Methods of prognosis and diagnosis of rheumatoid arthritis
US11609237B2 (en) Marker sequences for diagnosing and stratifying systemic sclerosis patients
US20180059107A1 (en) Method of detecting or diagnosing sjogren's syndrome based on the presence of auto-antibody against aquaporin 5
WO2012139052A2 (en) Antibody biomarkers for diabetes
Kaga et al. Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA
US11719694B2 (en) Biomarkers in autoimmune liver disease
CN107436358A (zh) 人结缔组织生长因子在制备类风湿性关节炎诊断试剂或试剂盒中的应用
Gautam Anti-Nuclear antibodies: current concepts and future direction for diagnosing connective tissue disease
EP3701264A1 (en) Method and means for diagnosing autoimmune hepatitis using autoantibody markers
US20130330745A1 (en) Methods of prognosis and diagnosis in sepsis
JP5605375B2 (ja) Ｋｕ８６に対する自己抗体の免疫測定方法、それに用いるキット、及びそれを用いた原発性肝細胞癌の判定方法
CN118878662A (zh) 多肽及其应用、试剂盒及其应用
Class et al. Patent application title: METHODS OF PROGNOSIS AND DIAGNOSIS OF RHEUMATOID ARTHRITIS Inventors: Kaori Morota (Chiba-Ken, JP) Ryotaro Chiba (Chiba-Ken, JP) Rika Sekiya (Chiba-Ken, JP) Assignees: ABBOTT JAPAN CO., LTD.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD PATENTEE MASSACHUSETTS GENERAL HOSPITAL

HB Alteration of name in register

Owner name: MASSACHUSETTS GENERAL HOSPITAL

Free format text: FORMER NAME(S): AMBERGEN, INC.

Owner name: AMBERGEN, INC.

Free format text: FORMER NAME(S): AMBERGEN, INC.